FDA Mandates Labeling Updates for OTC Weight Loss Drug alli (Orlistat) Warning of Kidney Stone and Kidney Injury Risk

What this means for your practice

This FDA action underscores the ongoing regulatory scrutiny of even over-the-counter medications, particularly those used for weight management, which is a common area of patient inquiry across many healthcare specialties. For telehealth providers, medspas, dental practices, chiropractic offices, and other healthcare businesses, this update highlights the critical importance of patient education and comprehensive intake processes. While alli is OTC, patients may ask providers for guidance on weight loss or mention its use during other appointments. Practitioners should be aware of this updated safety information when counseling patients on weight management strategies, reviewing patient medication lists, or evaluating symptoms that could be indicative of acute kidney injury or kidney stones. It reinforces the need for providers to proactively inquire about all medications and supplements a patient is taking, including OTC products, and to be prepared to advise on potential risks and when to seek immediate medical attention. Offering clear, evidence-based guidance on OTC products can enhance patient safety and reinforce a practice's commitment to comprehensive care, even when not directly prescribing.

Washington D.C. — The U.S. Food and Drug Administration (FDA) has announced significant revisions to the 'Drugs Facts Label' for the over-the-counter (OTC) weight loss medication, alli (orlistat) 60 mg capsules. These changes are designed to inform consumers and healthcare professionals about rare but serious risks associated with the drug, specifically concerning kidney health.

Regulatory Action and New Warnings

The FDA has approved updates to the labeling of alli (orlistat) 60 mg capsules to include warnings regarding the potential for acute kidney injury. This is a rare, yet serious, side effect of the medication. The revised labeling now explicitly advises consumers to:

• Consult a healthcare provider before using alli if they have a history of kidney disease or kidney stones.
• Stop using alli and seek medical attention immediately if they experience symptoms indicative of kidney injury or kidney stones. Such symptoms include back or groin pain, painful urination, blood in the urine, feet and leg swelling, or less frequent urination.

These critical warnings regarding renal (kidney) injury are now standardized across all FDA-approved orlistat products. This includes both the OTC alli (60 mg capsules) and its higher-strength prescription counterpart, Xenical (orlistat) 120 mg capsules.

Background on Orlistat Products

orlistat is a lipase inhibitor, functioning by binding to enzymes responsible for breaking down dietary fats. This mechanism reduces the amount of dietary fat absorbed from the digestive tract.

• alli (orlistat) 60 mg capsules: This is the only FDA-approved nonprescription weight loss aid. It is approved for use by overweight adults aged 18 and older, in conjunction with a reduced-calorie and low-fat diet.
• Xenical (orlistat) 120 mg capsules: This prescription-strength product is indicated for obesity management, including both weight loss and maintenance, when used alongside a reduced-calorie diet. It also aims to reduce the risk of weight regain following prior weight loss.

Understanding the Kidney-Related Risks

The FDA's decision to update the labeling stems from rare reports of specific kidney-related side effects in individuals taking orlistat. These include:

• Acute Kidney Injury: A condition where the kidneys suddenly lose their ability to filter waste products from the blood, potentially leading to a dangerous buildup of waste. While mild cases may be reversible, severe, untreated cases can be fatal.
• Hyperoxaluria: Characterized by abnormally high levels of oxalate, a waste product, in the urine. Oxalate is naturally produced by the liver and also ingested through diet.
• Calcium Oxalate Nephrolithiasis: Commonly known as kidney stones, these form when oxalate combines with calcium within the urinary tract.
• Oxalate Nephropathy: A condition where calcium oxalate crystals accumulate within the kidneys, interfering with normal kidney function.

Recommendations for Consumers

Consumers are urged to:

• Read the 'Drugs Facts Label' carefully before commencing treatment with alli. This is particularly important for OTC medications, as consumers may not have consulted a healthcare provider prior to use.
• Be aware of the rare but serious risks, including acute kidney injury, hyperoxaluria, calcium oxalate nephrolithiasis, and oxalate nephropathy.
• Seek medical advice from a healthcare provider before taking alli if they have a personal history of kidney disease or kidney stones.
• Immediately stop taking alli and consult a healthcare provider if they develop any symptoms of acute kidney injury or kidney stones. These symptoms include back or groin pain, painful urination, blood in the urine, swelling in the feet and legs, or a decrease in the frequency of urination.
• Discuss any side effects or lack of response to alli with a healthcare provider to explore alternative treatment options.

Recommendations for Health Care Professionals

Healthcare professionals, especially those involved in weight loss counseling, should:

• Inform patients about the rare reports of acute kidney injury, hyperoxaluria, calcium oxalate nephrolithiasis, or oxalate nephropathy associated with orlistat products.
• Advise patients to discontinue the drug and proceed with appropriate evaluation and management if they present with signs of acute kidney injury or nephrolithiasis while taking alli.

This FDA action emphasizes the ongoing commitment to patient safety and the critical role of informed decision-making in the use of both prescription and over-the-counter medications.

Key Facts

| Detail | Value | |---|---| | Affected Products | alli (orlistat) 60 mg capsules (OTC); Xenical (orlistat) 120 mg capsules (prescription) | | Regulatory Action | FDA approved changes to the 'Drugs Facts Label' for OTC alli | | New Warnings | Risk of acute kidney injury, hyperoxaluria, calcium oxalate nephrolithiasis (kidney stones), and oxalate nephropathy | | Consumer Advice | Ask a health care provider before using if you have kidney disease/stones; stop use and seek doctor if kidney injury symptoms appear | | Consistent Labeling | Kidney injury risks now described consistently across all FDA-approved orlistat products (OTC and prescription) | | Audience | Consumers, Patients, Health Care Providers, Pharmacy, Gastroenterology, Nephrology, Endocrinology |

Frequently Asked Questions

What is the new warning on the alli (orlistat) label?

The new warning on the alli (orlistat) label is about the risk of acute kidney injury, which includes kidney stones (calcium oxalate nephrolithiasis), high urinary oxalate levels (hyperoxaluria), and kidney damage from oxalate crystals (oxalate nephropathy).

Should my patients talk to a doctor before taking alli?

Yes, the updated labeling advises consumers to ask a health care provider before using alli if they have ever had kidney disease or kidney stones.

What symptoms should I tell patients to look out for that might indicate a kidney problem?

Patients should be advised to stop using alli and ask a doctor if they develop symptoms of kidney injury or kidney stones, such as back or groin pain, painful urination, blood in the urine, feet and leg swelling, or less frequent urination.

Does this warning apply to both the OTC and prescription versions of orlistat?

Yes, the risk of renal (kidney) injury is now described consistently across the labeling for all FDA-approved orlistat products, including the OTC alli (60 mg) and the higher-strength prescription Xenical (120 mg).

What should I do as a healthcare professional if a patient taking alli shows signs of kidney issues?

If a patient taking alli presents with signs of acute kidney injury or kidney stones, you should advise them to stop the drug and proceed with appropriate evaluation and management.

Source: FDA — FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury · Wed, 10 Jun 2026 12:08:00 EDT